Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fibrocell acquires rights from UCLA; seeks a lead on adult mesenchymal stem cells from dermal skin cells

This article was originally published in Clinica

Executive Summary

Fibrocell Science, a US regenerative cell therapy firm, has been keeping quite busy since US launch in October 2011 of its autologous aesthetic cell therapy laViv (azficel-T), which is indicated to improve smile lines and uses a patient's own collagen-making skin cells, or fibroblasts. The company is venturing into new areas – the most exciting of which is adult mesenchymal stem cells which are derived from dermal skin cells – and is sponsoring a scientific initiative with top academics to try to secure grant funding that will advance many clinical research programmes.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT098919

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel